Search results for "NextEpochMarket web presence.ckc" in Conferences / Events

The session will cover market participants views on this type of insurance in M&A transactions. Speakers will cover key matters such as:

• When is the appropriate time to engage a broker

• How relevant is the brand of the due diligence provider to the terms and condition of the policy

• How to treat the disclosures and specific indemnities in the agreements of the transaction and of course

• Will they pay in the future?

• Beyond M&A: insuring withholding, VAT, TP and RETT risks
• Insurance-linked structures in capital planning
• Claims, exclusions, premium sizing and jurisdictional evolution
• UK, USA, Spain: mature insurance markets; Italy emerging
• Client strategies for using tax insurance as deal protectors
• Broker and underwriter engagement: building tax certainty
• Case studies in active claims and coverage resolutions
• Underwriting tax structuring with dispute anticipation

Reporter

Mark Galea Salomone WH Partners, Ta' Xbiex

• 1.Impact of European Data Laws on USA and Asia
• 2.Cybersecurity and AI (AI and cybersecurity risks and regulation/tech policies)
• 3.What's hot in the USA
• 4.Copyright ownership for AI generated content
• 5.Patentability of inventions created using AI tools
• 6.IP infringement involving digital or virtual goods (in online games etc)
• 7.Cross-border M&A: navigating regulatory and compliance hurdles
• 8.Structuring earnouts and navigating employee equity in startup Acquisitions
• 9.Strategic vs. financial investors: the impact on startups in VC / PE deals

The session will cover the legal issues arising from blocking of web sites. Such sites may be actively managed by social media accounts who may block access based on their own internal policies, i.e. in respect of hate speech, fraud or user complaints, or such web sites may be passively managed internet service provides where protection against infringement must be enforced by private action. Particular issues concern rolling web site blocking orders to control signal piracy of live broadcasts.

Topic one: Shortage of drugs
Moderators
María Alonso  Lilly Spain, Madrid
Camilla Appelgren  Mannheimer Swartling, Stockholm 
Ruta Pumputiene  Ellex Valiunas, Lithuania

Topic two: The current surge and challenges of digital therapeutics
Moderators
Adem Koyuncu  Covington, Brussels
Elisa Stefanini  Portolano Cavallo, Milan
Cécile Théard-Jallu  De Gaulle Fleurance & Associés, Paris

Topic three: Financing of advanced new therapies
Moderators
Mireia Castro  Novartis Spain, Barcelona
Alfonso Gallego  Pfizer, Madrid 

Topic four: E-commerce of medicinal products: Global freedom or national restrictions?
Moderators
José Fernández Rañada  Garrigues, Madrid 
Markus Schott  Bär & Karrer, Zurich
Dr Katharina Wodarz  Raue, Berlin

Topic five: Product liability and medical devices
Moderators
Manuel Durães Rocha  Abreu Advogados, Lisbon
Monika Gattiker  Lanter, Zurich  

Topic six: Gene therapies and orphan drugs - regulatory status and reimbursement
Moderators
Henar Álvarez  Alnylam Pharmaceuticals, Madrid
Ariadna Padilla  Takeda, Madrid

Topic seven: Re-labelling repackaging and parallel import of medical devices and pharmaceuticals
Moderators
Maria Cedó  Esteve, Barcelona 
Janine Demont-Reudt  Niederer Kraft Frey, Zurich  
Miguel Ángel Galve  ex GC of Elanco, Madrid

Topic eight: Human research – big data and secondary use of data
Moderators
Beatriz Cocina Arrieta  Uria Menendez, Madrid
Ioanna Michalopoulou  Michalopoulou & Associates, Athens
Lincoln Tsang Ropes & Gray, London

Topic nine: Deal structures of life sciences transactions
Moderators
Gustavo Alcocer Lugo  Olivares, México City
Elazar Stein  Medison Pharma, Petach Tikva and Zug, Israel
Emmanuelle Trombe  McDermott, Will & Emery, Paris 

Topic ten: Interplay between regulation and intellectual property - review of Bolar exemption
Moderators
Rais Amils  Pérez Llorca, Madrid
Özge Atilgan Karakulak  Gün + Partners, Istanbul 
Martin Dræbye Gantzhorn  Bech-Bruun, Copenhagen

Topic eleven: Artificial intelligence and life sciences
Moderators
James Gallagher  Mason Hayes & Curran, Dublin 
Njeri Mutura  Microsoft, Irvine, California 
Josefine Sommer  Sidley Austin LLP, Brussels

Topic twelve: Trade secrets / confidentiality in R&D collaborations
Moderators
Dr Hussein Akhavannik  Blank Rome, Washington, District of Columbia
Maarten Schut  Kennedy Van der Laan, Amsterdam

Topic thirteen: Recent landscape on foreign direct investment in medtech/pharma
Moderators
Per Lagerkvist  MAQS, Stockholm
Irene Fernández Puyol  Gómez-Acebo & Pombo, Madrid

Topic fourteen: Unified patent court – takeaways from the first year
Moderators
Morten Bruus  Accura, Copenhagen
Francine Le Péchon-Joubert  De Gaulle Fleurance, Paris
Hanna Tilus  Cirio, Stockholm

Topic fifteen: Pharmaceuticals disparagement cases –Interactions with HCPs and regulators from a competition law perspective
Moderators
Luis Alcover  Faus Moliner, Barcelona
Moisés Ramírez  GSK Spain, Madrid 
Anders Thue Simonsen Vogt Wiig, Oslo

Topic sixteen: Advertising pharmaceuticals - old law for modern information needs
Moderators
Ariadna Casanueva  Cuatrecasas, Barcelona
Viviana Cervieri  Cervieri Monsuárez, Montevideo
Celine Weber  Walder Wyss, Zurich

Topic seventeen: Securing innovation: Tackling the 21st century epidemic of counterfeiting and intellectual property piracy
Moderators
Francisco Javier García  Uría Menéndez, Barcelona
Jason Jardine  Knobbe Martens, San Diego, California
Luis Ruiz BPL, Guatemala City

As global demand for critical minerals intensifies, access to these inputs is no longer determined solely by geology or investment conditions; it increasingly depends on a complex web of export controls, sanctions regimes, trade restrictions and market-driven allocation mechanisms.